secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001628280-24-035223
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aquestive Q2 revenue up 52% to $20.1M; narrows net loss; raises FY guidance
---------------------------------------------------------------------------

- Total revenue $20.1M vs $13.2M YoY; net loss $2.7M ($0.03/sh) improves from $5.8M loss.
- Non-GAAP adjusted EBITDA positive $1.8M vs -$3.3M; cash $89.9M.
- Raises FY24 revenue guidance to $57-60M (prev. $48-51M); adj. EBITDA loss guidance narrowed to $20-23M.
- Anaphylm NDA submission on track for Q1 2025; launch expected end 2025/early 2026.
- Libervant expanded to ages 2-5; national retail distribution expected Q4 2024; epinephrine prodrug investor day planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000162828024035223/0001628280-24-035223-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000162828024035223/aqst-20240806.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-035223

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer